The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
And you can say, well, Peter, how can you take or prescribe rapamycin for GRo protective effects, when we do not have a human clinical trial demonstrating that it lengthens life? And the answer is, because I have 84 other pieces of data that all point in the same direction across every model organism going back more than a billion years.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
And the answer is, because I have 84 other pieces of data that all point in the same direction across every model organism going back more than a billion years.
you know i think rapamycin is an amazing agent here and i think it's one that warrants lots of investigation in humans because i think that the non-human literature are so compelling right both in terms of the actual drug use and also the mechanism of action and the genetic manipulation all the way from you know worms fruit flies obviously you know mice yeast matt caberlin's dogs it just over and over and over again demonstrates efficacy
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.